Suchergebnisse - "d'Arminio Monforte, Antonella"

PubPharm (27)

1

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen : The "STORE" Study

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2020

von Gori, A. | Antinori, A. | Vergori, A. | +22

2

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis : Findings From a Randomized Study

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2019

von Rossetti, B. | Gagliardini, R. | Sterrantino, G. | +20

3

Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients

enthalten in: HIV clinical trials | 2018

von Dentone, C. | Di Biagio, A. | Cozzi Lepri, A. | +10

4

Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients

enthalten in: PloS one | 2018

von Taramasso, L. | Di Biagio, A. | Bovis, F. | +30

5

Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS) : a prospective observational study

enthalten in: The lancet. Gastroenterology & hepatology | 2017

von Petta, S. | Marzioni, M. | Russo, P. | +123

ErratumIn: Lancet Gastroenterol Hepatol. 2017 Jun;2(6):e3. - PMID 28497762

6

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy : 48-week results of a randomized trial

enthalten in: PloS one | 2017

von Rossetti, B. | Gagliardini, R. | Meini, G. | +28

7

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients

enthalten in: PloS one | 2017

von Gianotti, N. | Cozzi-Lepri, A. | Antinori, A. | +11

8

Atazanavir/ritonavir monotherapy : 96 week efficacy, safety and bone mineral density from the MODAt randomized trial

enthalten in: The Journal of antimicrobial chemotherapy | 2016

von Galli, L. | Spagnuolo, V. | Bigoloni, A. | +55

9

Fosamprenavir/ritonavir in patients with viral hepatitis coinfection : an observational multicohort study

enthalten in: HIV clinical trials | 2016

von Nasta, P. | Salmon, D. | d'Arminio Monforte, A. | +5

10

T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor in HIV-infected late presenters : results from a retrospective, ex vivo study

enthalten in: Antiviral therapy | 2016

von Tincati, C. | Savoldi, A. | Cannizzo, E. | +6